.png){kind=icon}
.png){kind=icon}
Return
The return of “goals” in the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia
.png){kind=icon}
PRE
AI
Z
A
DOI：10.1016/j.jacl.2026.06.006.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• The 2026 ACC/AHA Guideline on the Management of Dyslipidemia reinstates LDL-C and non–HDL-C goals after a decade of primarily intensity/threshold-based recommendations. • Treat-to-target goals can improve clinical directionality, follow-up, and patient-clinician communication. • LDL-C, non–HDL-C, and apoB provide complementary views of atherogenic lipoprotein burden, especially in discordant metabolic states. • Goal reinstatement has implications for quality measurement, health policy, and equity in dyslipidemia care.
Journal
IF:
4.6
Papers:
2.5K
Citations:
4.3K
Organization
No organization information available
Cited Papers